
Vesalius and LRM back Complix
Vesalius Biocapital and LRM have backed Belgian pharmaceutical company, Complix NV.
The Luxembourg -based Public Research Centre for Health, or CRP Santé, also joined both venture capital firms in the €5m series-A funding round.
Complix focuses on the discovery and development of medicines based on "Alphabodies", which are known to have therapeutic capabilities. The company opened an office in Luxembourg and is working together with CRP Santé to develop its Alphabody therapy product, which is designed to fight against viral diseases.
The unquote" team is currently researching this transaction. In-depth deal information for subscribers will follow shortly.
If you have any information regarding this transaction, please contact Alexandra Carrera on +44 20 7004 7527 or alexandra.carrera@incisivemedia.com
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater